ArticlePakistan journal of medical sciences2025
Risk factors for major cardiovascular adverse events and the effects of sacubitril/valsartan in patients with acute myocardial infarction after Percutaneous Coronary Intervention.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the risk factors for major cardiovascular adverse events (MACEs) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), and observe the effect of sacubitril/valsartan (SV) on these events. Methods: This was a retrospective study. One hundred and twenty-five patients with AMI undergoing PCI admitted to The First Affiliated Hospital of Yangtze University from January 2022 to August 2024 were included and divided into MACEs group(n=54) and non-MACEs group(n=71) according to whether MACEs occurred one week after PCI. Univariate/multivariate logistics regression analysis of risk factors for MACEs. Patients were divided into SV group(n=65) and non-SV group(n=60) according to whether taking SV, adverse events, blood lipids, hemorheology, and cardiac function were compared using Chi-square or t-test. Results: The incidence of MACEs was 43.20% (54/125). Logistics regression analysis showed that an age of ≥70 years, smoking history, hyperlipidemia, anemia, hypertension grade≥2, and time from onset to balloon dilation ≥7 hours were independent risk factors for MACEs. The incidence of MACEs was 30.78% in SV group, lower than non-SV group (56.67%) (χ Conclusion: Use of SV can improve blood lipids, hemorheology, and cardiac function, and reduce the incidence of post-PCI MACEs in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.